Yahoo Finance • 9 hours ago
NOVATO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today repo... Full story
Yahoo Finance • 2 days ago
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is among the most promising biotech stocks to buy according to hedge funds. According to a recent disclosure with the SEC, Assenagon Asset Management S.A. lifted its holdings in Ultragenyx Pharm... Full story
Yahoo Finance • 3 days ago
NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective September 22, 2025, fo... Full story
Yahoo Finance • 8 days ago
[FDA Approved Products or Drugs] Olivier Le Moal Regeneron Pharmaceuticals (NASDAQ:REGN [https://seekingalpha.com/symbol/REGN]) announced on Friday that the U.S. FDA approved a label expansion for its anti-cholesterol agent Evkeeza, marke... Full story
Yahoo Finance • 18 days ago
Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q2 2025 investor letter. A copy of the letter can be downloaded here. U.S. large-cap growth equities recovered from a sharp sell-off in e... Full story
Yahoo Finance • 25 days ago
[Rare disease. health problem. woman doctor showing words written on a tablet.] * Ultragenyx Pharmaceutical (NASDAQ:RARE [https://seekingalpha.com/symbol/RARE]) said that week 96 phase 3 data of its gene therapy DTX401 for glycogen stor... Full story
Yahoo Finance • 25 days ago
At Week 96 participants experienced even greater reductions in daily cornstarch intake while maintaining low levels of hypoglycemia, improved levels of euglycemia and improved fasting tolerance Phase 3 results are further supported by ear... Full story
Yahoo Finance • last month
NOVATO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic dise... Full story
Yahoo Finance • last month
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Pe... Full story
Yahoo Finance • last month
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Pe... Full story
Yahoo Finance • 2 months ago
Investing.com - Ultragenyx (NASDAQ: RARE) reported second quarter EPS of $-1.17, $0.13 better than the analyst estimate of $-1.30. Revenue for the quarter came in at $166.5M versus the consensus estimate of $161.97M. Ultragenyx’s stock... Full story
Yahoo Finance • 2 months ago
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE [https://www.chartmill.com/stock/quote/RARE/profile]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company’s revenue and e... Full story
Yahoo Finance • 2 months ago
Second quarter total revenue of $166 million, Crysvita® revenue of $120 million and Dojolvi® revenue of $23 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $4... Full story
Yahoo Finance • 2 months ago
NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic disea... Full story
Yahoo Finance • 3 months ago
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biotechnology company focused on developing novel therapies for rare and ultra-rare diseases, stands at a critical juncture in its journey. With several key clinical trials underway and a di... Full story
Yahoo Finance • 3 months ago
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 14, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RAR... Full story
Yahoo Finance • 3 months ago
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story
Yahoo Finance • 3 months ago
TORONTO - Health Canada has approved Ultragenyx Pharmaceutical Inc.’s (NASDAQ:RARE) Evkeeza (evinacumab) for children as young as 6 months old with homozygous familial hypercholesterolemia (HoFH), the company announced Monday. The announce... Full story
Yahoo Finance • 3 months ago
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the stocks drowned heavily. Are you holding any? Ultragenyx fell by 26.05 percent week-on-week as investor sentiment was largely dragged down by the Food and Drug Administration’s (FD... Full story
Yahoo Finance • 3 months ago
[Paper with words Sanfilippo syndrome and glasses.] * The U.S. FDA has issued a Complete Response Letter to Ultragenyx Pharmaceutical (NASDAQ:RARE [https://seekingalpha.com/symbol/RARE]) for its BLA for UX111 (ABO-102), its AAV gene the... Full story